サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：遺伝子組み換えB型肝炎ワクチン市場2022-2028
市場調査レポート
商品コード
1215769

遺伝子組み換えB型肝炎ワクチン市場2022-2028

Recombinant Hepatitis B Vaccine Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
遺伝子組み換えB型肝炎ワクチン市場2022-2028
出版日: 2023年01月20日
発行: Orion Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の組み換えB型肝炎ワクチン市場は、予測期間中に5.6%の大幅なCAGRで成長すると予測されています。市場成長の主な要因は、B型肝炎の流行が拡大していることで、B型肝炎ワクチンの接種と生産に対する需要が大規模に急増していることです。この業界で事業を行う企業は、事業を拡大し、市場での競争力を維持するために、他の市場プレイヤーとの協力に注力しています。例えば、2021年5月、Dynavax Technologies Corp.は、ドイツにおけるHEPLISAV B[Hepatitis B Vaccine（Recombinant）, Adjuvanted]の販売と流通についてBavarian Nordicと商業化契約を締結しました。HEPLISAV Bは、米国食品医薬品局（FDA）および欧州委員会（EC）が承認した唯一の成人向けB型肝炎ワクチンで、2回接種のレジメンを1ヶ月で完了させることができます。しかし、B型肝炎ワクチンに伴う副作用が市場成長の妨げになると予想されています。

世界の組換えB型肝炎ワクチン市場は、種類と用途に基づいて区分されます。タイプに基づいて、市場は10mcg/mlと10mcg/0.5mlに二分されます。用途に基づき、市場は新生児/小児と成人に細分化されます。

地域的には、組み換えB型肝炎ワクチン市場は、北米、欧州、アジア太平洋地域、世界のその他の地域に区分されます。北米は予測期間中、市場で最も高いシェアを占めると予想されます。肝臓がんの増加によるB型肝炎ワクチンへの高い需要は、地域の市場成長を促進する顕著な側面です。B型肝炎ワクチンは、がんによる死亡原因の第2位である肝臓がんの予防に役立つことから、最初の抗がん剤ワクチンとされています。米国がん協会の推計によると、2022年に原発性肝がんと肝内胆管がんについて、米国では約41,260人が新たに診断され（男性28,600人、女性12,660人）、30,520人（男性20,420人、女性10,100人）がこれらのがんで死亡すると予想されています。それが組換えB型肝炎ワクチンの需要増につながるのです。

目次

第1章 レポート概要

  • 現在の産業分析と成長性の展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要とインサイト

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • レコメンデーション
    • まとめ

第3章 競合情勢

  • 主要企業の分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 組換えB型肝炎ワクチンの世界市場：タイプ別
    • 10mcg/ml
    • 10mcg/0.5ミリリットル
  • 遺伝子組換えB型肝炎ワクチンの世界市場：用途別
    • 新生児/小児
    • 成人

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域
    • ラテンアメリカ
    • 中東＆アフリカ

第6章 企業プロファイル

  • Bharat Biotech International Ltd.
  • CSL Ltd.
  • Dynavax Technologies Corp
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • KM Biologics（Meiji Holdings Co., Ltd.）
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt., Ltd.
  • Sinovac Biotech Ltd.
  • VBI Vaccines, Inc.
図表

LIST OF TABLES

  • 1. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL 10MCG/ML RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL 10MCG/0.5ML RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 5. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR NEWBORN/CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR ADULT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. NORTH AMERICAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 9. NORTH AMERICAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 10. NORTH AMERICAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 11. EUROPEAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. EUROPEAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 13. EUROPEAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 14. ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 15. ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 16. ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 17. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 3. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL 10MCG/ML RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL 10MCG/0.5ML RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR NEWBORN/CHILDREN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR ADULT MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 8. US RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 9. CANADA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 10. UK RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 11. FRANCE RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. GERMANY RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. ITALY RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. SPAIN RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. REST OF EUROPE RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. INDIA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. CHINA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. JAPAN RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. SOUTH KOREA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. REST OF ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026825

Title:Global Recombinant Hepatitis B Vaccine Market Size, Share and Trends Analysis, By Type (10mcg/ml and 10mcg/0.5ml), By Application (Newborn/ Children and Adult), Forecast Period (2022-2028).

The global recombinant hepatitis B vaccine market is anticipated to grow at a substantial CAGR of 5.6% during the forecast period. The market growth is majorly driven by the growing prevalence of hepatitis B which has surged the demand for hepatitis B vaccination and production on a large level. Companies operating in the industry are focusing on collaborating with other market players to expand their business and remain competitive in the market. For instance, in May 2021, Dynavax Technologies Corp. entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany. HEPLISAV B is the only US Food and Drug Administration (FDA) and European Commission (EC) approved hepatitis B vaccine for adults with a two-dose regimen that is completed in one month. However, the side effects associated with the hepatitis B vaccine are expected to hamper the market growth.

The global recombinant hepatitis B vaccine market is segmented based on type and application. Based on type, the market is bifurcated into 10mcg/ml and 10mcg/0.5ml. Based on application, the market is sub-segmented into newborns/children, and adults.

Geographically, the recombinant hepatitis B vaccine market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to contribute the highest share of the market during the forecast period. The high demand for hepatitis B vaccines due to increasing liver cancer is the prominent aspect driving the regional market growth. The hepatitis B vaccine is the first anti-cancer vaccine because it can help prevent liver cancer, which is the second most common cause of cancer death. As per the American Cancer Society's estimates for primary liver cancer and intrahepatic bile duct cancer in 2022, around 41,260 new cases (28,600 in men and 12,660 in women) will be diagnosed and 30,520 people (20,420 men and 10,100 women) will die of these cancers in the US. That will lead to an increase in demand for recombinant hepatitis B vaccines.

The major market players in the global recombinant hepatitis B vaccine market include Merck & Co., Inc., GlaxoSmithKline plc, Sanofi Pasteur, Dalian Hissen Bio-pharm, and Pfizer Inc., among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in January 2021, Dynavax Technologies Corp. announced the final immunogenicity and interim safety results of the ongoing clinical trial evaluating HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in patients undergoing hemodialysis. As per the company, the hemodialysis trial which reinforces the existing clinical data regarding the safety and ability of HEPLISAV-B provided high rates of protection for patients undergoing hemodialysis.

Research Methodology

The market study of the global recombinant hepatitis B vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Recombinant Hepatitis B Vaccine Research and Analysis by Type
  • Global Recombinant Hepatitis B Vaccine Research and Analysis by Application

The Report Covers:

  • Comprehensive research methodology of the global recombinant hepatitis B vaccine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global recombinant hepatitis B Vaccine market.
  • Insights about market determinants that are stimulating the global recombinant hepatitis B Vaccine market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Recombinant Hepatitis B Vaccine Market by Type
    • 4.1.1. 10mcg/ml
    • 4.1.2. 10mcg/0.5ml
  • 4.2. Global Recombinant Hepatitis B Vaccine Market by Application
    • 4.2.1. Newborn/Children
    • 4.2.2. Adult

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. Bharat Biotech International Ltd.
  • 6.2. CSL Ltd.
  • 6.3. Dynavax Technologies Corp
  • 6.4. Emergent BioSolutions Inc.
  • 6.5. GlaxoSmithKline PLC
  • 6.6. KM Biologics (Meiji Holdings Co., Ltd.)
  • 6.7. LG Chem Ltd.
  • 6.8. Merck & Co., Inc.
  • 6.9. Novartis AG
  • 6.10. Pfizer, Inc.
  • 6.11. Sanofi S.A.
  • 6.12. Serum Institute of India Pvt., Ltd.
  • 6.13. Sinovac Biotech Ltd.
  • 6.14. VBI Vaccines, Inc.